DSS, Inc (DSS) Fair Value & Analysis
Consumer Cyclical · US · Market cap $5.4M
Fair value as of: Jun 23, 2026
Analysis
DSS, Inc (DSS) currently trades at $0.5950, while our model-based Fair Value estimate is $4.13 — implying the stock looks roughly 594.1% undervalued today. We read business quality at 80/100 (high quality), in the Consumer Cyclical sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
DSS, Inc. operates in the product packaging, biotechnology, commercial lending, securities and investment management, and direct marketing businesses in the United States. The company manufactures, markets, and sells mailers, photo sleeves, custom folding cartons, and 3-dimensional direct mail solutions; and markets and distributes nutritional and personal care products. It invests in or acquires companies in the biohealth and biomedical fields, including businesses that focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases; and develops open-air defense initiatives for air-borne infectious diseases comprising tuberculosis and influenza. In addition, the company focuses on acquiring equity positions in undervalued commercial banks, bank holding companies, and nonbanking licensed financial companies; and companies engages in nonbanking activities related to banking, such as loan syndication, mo…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is DSS, Inc (DSS) undervalued?
What is the fair value of DSS?
What is the quality score of DSS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.